Astronaut Raphaël Liégeois will be carrying some rather unusual passengers in his luggage: dried blob samples, some of which have been irradiated with X-rays at UNamur. What are the Namur scientists hoping to achieve? They want to observe how this organism responds to the space environment and is able to repair its DNA in microgravity, and compare these results with those obtained in a similar experiment carried out on Earth. "In our laboratory, we simulate the stresses that the blob could undergo in space in order to assess its ability to survive and repair itself," explains Anne-Catherine Heuskin, professor in the Department of Physics.

While awaiting the rocket launch scheduled for 2027, researchers at UNamur are already actively preparing for the mission. For several months, they have been conducting a series of tests to ensure the reliability of the experiment: reaction to temperature variations, power failures, transport to the launch site in Florida, assembly of the mini-spacecraft that will house the samples, etc. "Every detail counts: even the choice of bags that protect the samples from light can influence the results," emphasizes Boris Hespeels.

Once on the ISS, Raphaël Liégeois will rehydrate the samples, culture them in a cabin on the station, and finally place them in a freezer at -80°C. "This procedure, which seems simple, becomes complex in zero gravity. We also have to ensure the stability of our samples, regardless of the timing of the experiment," continues Boris Hespeels. Inside the ISS, Raphaël Liégeois will have to carry out various experiments selected by the Belgian Science Policy Office (BELSPO). "And the order in which they will be carried out has not yet been determined," the two Namur-based researchers explain.  

Post-mission analyses will identify cellular protection mechanisms under extreme conditions. These results could inspire the development of protective molecules for astronauts or patients undergoing radiotherapy. "Space remains a hostile environment. Understanding how living organisms adapt to it is essential for preparing future exploration," Boris Hespeels points out.

Finally, the BeBlob project also has an educational component: activities based on the blob will be offered in schools to raise awareness among young people about scientific research and space exploration. An ambitious project is also under consideration to enable students aged 8 to 18 to work directly on samples that took part in Raphaël Liégeois' mission aboard the ISS.

The University of Namur is establishing itself as a key player in the study of the blob. Researchers at the LARN (Laboratory for Nuclear Reaction Analysis) and the ILEE (Institute of Life, Earth and Environment) and NARILIS (Namur Research Institute for Life Sciences) institutes have been conducting research into radiation resistance and DNA repair for several years. The BeBlob project builds on experience gained during previous space missions and active collaboration with ESA and BELSPO. The BeBlob project is one of three Belgian scientific experiments selected from 29 projects to be carried out during Belgian astronaut Raphaël Liégeois' mission scheduled for 2027. This scientific expertise places UNamur at the heart of space biology and fundamental research on life in extreme environments. The project is part of UNIVERSEH, the ERASMUS+ alliance of European universities that aims to build a "European university" focused on the space sector, of which UNamur is a member. 

What led you to specialize in the field of aging?

It all started with my doctoral thesis. I was offered the opportunity to work on sarcopenia, a subject that was relatively unexplored in 2012. It was the very beginning: people were just starting to talk about this disease. I was immediately interested in the topic and quickly realized that research in this field was still in its infancy! I launched a cohort study of 530 patients over the age of 65 who were followed for about ten years. This data led to the publication of numerous studies. It was not until 2016 that sarcopenia was recognized as a distinct pathology. Until then, it was little known to the general public and health professionals. In addition, there were many different definitions of the disease, which added to the complexity. I joined an international group of experts, the GLIS (Global Leadership Initiative in Sarcopenia), which is currently working to establish a global, consensus-based definition of sarcopenia. We are finally moving towards a clear definition and greater awareness of the disease, particularly among doctors.

So how do we define sarcopenia?

Today, sarcopenia is defined as a progressive and generalized loss of muscle strength and mass with advancing age, beyond the physiological threshold. Everyone loses muscle as they age, but we have noticed that some people lose much more than others. We are seeking to understand this interindividual variability, which is influenced by many factors, including genetic and metabolic factors.

What percentage of people are affected?

This disease affects a huge number of elderly people. It is estimated that between 10 and 16% of people over 65 suffer from sarcopenia. This figure rises to 60% for people hospitalized in an oncology ward, for example. 

Why does it deserve special attention?

In addition to its high prevalence, it has serious consequences: falls, fractures, hospitalizations, loss of independence, reduced quality of life and, very clearly, increased mortality. Numerous studies are also beginning to show the significant healthcare costs associated with sarcopenia. The impact of sarcopenia therefore extends beyond the individual; we can talk about a real societal impact!

Do you think it is an underestimated public health issue?

It certainly was a few years ago, but the situation is changing. Research is booming and the media is starting to take an interest. Politicians are also paying more and more attention to it, which is very positive. We all want to age well and preserve our physical abilities.

You have developed a specific tool, the SarQol. What is it?

SarQol is a quality of life questionnaire specific to sarcopenia, created ten years ago. The term "specific" is particularly apt, because previously generic tools were used to measure quality of life, which only partially measured its real impact. I have received a huge number of requests to use and translate this questionnaire. It has now been translated into more than forty languages! In view of this enthusiasm, I carried out a meta-analysis which unanimously showed a clear decline in the quality of life of patients with sarcopenia. 

This tool is representative of a "patient-centered" approach. How does this approach work in practice?

Clinical research tends to involve the patient more in the care process. If the patient feels listened to and understood, this will influence their condition. SarQoL is part of this approach, as is the Discrete Choice Experiment (DCE) technique, which I am particularly interested in. This is a study of patient preferences in terms of treatment characteristics. To date, there is no drug treatment for sarcopenia. This type of study will therefore enable the pharmaceutical and agri-food industries to offer pharmacological treatments or nutritional supplements tailored to patient preferences. By taking these preferences into account, we can achieve better treatment adherence and, therefore, better results.

In addition to your role as a researcher, you are also an expert in methodology. What does that involve?

Discrete choice experiments (DCEs), like meta-analyses, are methods that can be applied to many areas of research. I am therefore regularly contacted by researchers and clinicians in the health sector, but not only, to apply these tools to their research topics in a practical way. I am very fond of this kind of collaboration, which feeds my scientific curiosity.

The "Credits & Projects" call for proposals resulted in 12 grants being awarded for ambitious new projects. These include two "equipment" grants, eight "research credits (CDR)" grants, and two "research projects (PDR)" grants, one of which is in collaboration with the ULB. The FRIA call for doctoral research support will fund eleven doctoral scholarships and the FRESH call will fund three. 

Two prestigious Scientific Impulse Mandates (MIS) were also obtained. This three-year funding supports young permanent researchers who wish to develop an original and innovative research program by acquiring scientific autonomy within their department.  

We would also like to highlight the two projects funded under the "WelCHANGE" call, a funding instrument for research projects with potential societal impact, led by a principal investigator in the humanities and social sciences.

Call for Equipment  

• Xavier De Bolle, Narilis Institute, Co-promoter in collaboration with UCLouvain
• Luca Fusaro, NISM Institute 

Call for Research Grants (CDR) 

• Marc Hennequart, NARILIS Institute
• Nicolas Gillet, NARILIS Institute
• Jean-Yves Matroule, NARILIS Institute
• Patricia Renard, NARILIS Institute
• Francesco Renzi, NARILIS Institute
• Stéphane Vincent, NISM Institute
• Laurence Meurant, NaLTT Institute
• Emma-Louise Silva, NaLTT Institute  

Call for Research Projects (PDR) 

• Jérémy Dodeigne, Transitions Institute, Co-supervisor in collaboration with ULB
• Luc Henrard, NISM Institute; Co-supervisor: Yoann Olivier, NISM Institute 

Fund for Training in Research in Industry and Agriculture (FRIA)

• Emma Bongiovanni - Supervisor: Catherine Michaux, NISM Institute
• Simon Chabot - Supervisor: Carine Michiels, Narilis Institute; Co-supervisor: Anne-Catherine Heuskin, Narilis Institute
• Lee Denis - Supervisor: Muriel Lepère, ILEE Institute
• Maé Desclez - Supervisor: Johan Yans, ILEE Institute; Co-supervisor: Hamed Pourkhorsandi (University of Toulouse)
• Pierre Lombard - Supervisor: Benoît Muylkens, Narilis Institute; Co-supervisor: Damien Coupeau, Narilis Institute
• Amandine Pecquet - Supervisor: Nicolas Gillet, Narilis Institute; Co-supervisor: Damien Coupeau, Narilis Institute
• Kilian Petit - Supervisor: Henri-François Renard, Narilis Institute; Co-supervisor: Xavier De Bolle, Narilis Institute
• Simon Rouxhet - Supervisor: Catherine Michaux, NISM Institute; Co-supervisor: Nicolas Gillet, Narilis Institute
• William Soulié - Supervisor: Yoann Olivier, NISM Institute
• Elisabeth Wanlin - Supervisor: Xavier De Bolle, Narilis Institute
• Laura Willam - Supervisor: Frédérik De Laender, ILEE Institute 

Fund for Research in the Humanities (FRESH) 

• Louis Droussin - Supervisor: Arthur Borriello, Transitions Institute; Co-supervisor: Vincent Jacquet, Transitions Institute
• Nicolas Larrea Avila - Supervisor: Guilhem Cassan, DeFIPP Institute
• Victor Sluyters – Supervisor: Wafa Hammedi, NADI Institute
• Amandine Leboutte - Co-supervisor: Erika Wauthia (UMons); Co-supervisor: Cédric Vanhoolandt, IRDENa Institute.

Scientific Impulse Mandate (MIS) 

• Charlotte Beaudart, Narilis Institute
• Eli Thoré ILEE Institute 

WelCHANGE Call  

• Nathalie Burnay Transitions Institute, in collaboration with UCLouvain
• Catherine Guirkinger, DeFIPP Institute

Congratulations to all! 

Scientific discoveries are like great stories: they often begin with an encounter. Nearly 20 years ago, Professor Stéphane Vincent of UNamur's Laboratoire de Chimie Bio-Organique, then a young sugar chemist, was in search of something new. During a post-doctorate in Strasbourg, France, in the laboratory of Jean-Marie Lehn, winner of the 1987 Nobel Prize in Chemistry and a specialist in supramolecular chemistry, he befriended another post-doctoral fellow: the Romanian Mihail Barboiu, now a CNRS researcher in Montpellier.

Soon before the Covid-19 pandemic, at a scientific congress, Mihail Barboiu showed Stéphane Vincent the results of his experiments. "He was using DCFs as a kind of transporter, to bring genes (DNA or RNA fragments) into a cell", recalls the chemist. "I then realized that DCFs were positively-charged molecules and readily adapted to DNA, which is negatively-charged. This gave me the idea of using them against bacteria, in the same way as certain antibiotics, which are also positively charged."

The two researchers then established an initial research project, with a thesis funded in cotutelle by UNamur, which culminated in 2021 in the publication of the first results showing the antibacterial activity of DCFs. "At the time, I was already working on antibacterial approaches, particularly against Pseudomonas aeruginosa, a major pathogen that forms biofilms", explains Stéphane Vincent.

To combat antiseptics and antibiotics, bacteria proceed in several ways. In addition to developing mechanisms to block the functioning of antibiotics, they are able to aggregate or dock themselves to a surface, for example that of a medical implant, and cover themselves with a complex tangle of all sorts of molecules. The latter, known as biofilm, protects the bacteria from external aggression. These biofilms are a major public health problem, as they enable bacteria to survive even the most powerful antibiotics and are notably the cause of nosocomial diseases, infections contracted during a stay in a healthcare establishment.

"We have shown that certain DCFs are both capable of inhibiting biofilm production, but also of weakening them, thereby exposing bacteria to their environment", summarizes Stéphane Vincent.

Bolstered by these results and thanks to C2W, a "very competitive"European program that funds post-doctorates, Stéphane Vincent invited Dmytro Strilets, a Ukrainian chemist who had just completed his thesis under the supervision of Mihail Barboiu, to work in his laboratory on DCFs. The project, called TADAM and carried out in collaboration with researchers Tom Coenye of UGent and Charles Van der Henst of the VUB, then focused on the antibacterial and antibiofilm potential of DCFs against Acinetobacter baumannii, a bacterium which, along with Pseudomonas aeruginosa, is on the list of pathogens of greatest concern defined by the World Health Organization (WHO).

The TADAM project is based on an ingenious assembly: DCFs are associated with special molecules known as pillarenes. The latter form a sort of cage around a proven antibiotic molecule, levofloxacin, thus improving its bioavailability and stability. The DCFs then have the role of inhibiting and disintegrating the biofilm, to enable the pillarenes to deliver their antibiotic directly to the bacteria thus exposed.

The results obtained by Stéphane Vincent's team are spectacular: the DCF-pillararene-antibiotic assembly is up to four times more effective than the antibiotic used alone! Noting that little work had yet been done on the antibiotic effect of these new molecules, the researchers decided to protect their invention by filing a joint patent, before going any further.

For everything still remains to be done. Firstly, because despite more than convincing results, how the assembly works is still obscure. "All the study of the mechanism of action has yet to be done, says Stéphane Vincent. "How is the antibiotic arranged in the pillararene cage? Why do DCFs have antibiofilm activity? How do DCFs and pillararenes fit together? All these questions are important, not only to understand our results, but also to eventually develop new generations of molecules."

And on this point, Stéphane Vincent wants to be particularly cautious. "We all dream, of course, of a universal molecule that will work on all pathogens, but we have to be humble, he pauses. "I've been working with biologists for many years, and I know that biological reality is infinitely more complex than our laboratory conditions. But it's because our results are so encouraging that we must persevere down this path."

The chemist already has several leads: "We're going to test the molecules on bacteria"circulating"suspended in a liquid, which behave very differently. And then we're also going to work on clinical isolates of pathogenic bacteria, to get a little closer to the real conditions under which these biofilms form."

Dmytro Strilets has just received a Chargé de Recherche mandate from the FNRS to develop second-generation DCFs and study their mode of action. The TADAM project has received funding from the University of Namur and the European Union's Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement n°101034383.